3,3-双(氯甲基)氧杂环丁烷 | 78-71-7

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 环烃
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环丁烷
• 中文名称: 3,3-双(氯甲基)氧杂环丁烷
• 中文别名: 3,3-二(氯甲基)氧杂环丁烷；3,3-双氯甲基氧杂环丁烷；3,3-双氯甲基-1-氧杂环丁烷
• 英文名称: 3,3-bis(chloromethyl)oxetane
• 英文别名: 3,3-bis(chloromethyl)oxacyclobutane
• CAS: 78-71-7
• 化学式: C₅H₈Cl₂O
• mdl: MFCD00027377
• 分子量: 155.024
• InChiKey: CXURGFRDGROIKG-UHFFFAOYSA-N

物化性质

• 熔点：
  18.7°C
• 沸点：
  198 °C(lit.)
• 密度：
  1.29 g/mL at 25 °C(lit.)
• 闪点：
  114 °C
• 物理描述：
  The monomer unit of a thermoplastic resin trademarked Penton.
• 颜色/状态：
  Finely divided powder for coatings
• 保留指数：
  1077

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 副作用

神经毒素 - 其他中枢神经系统神经毒素 肾毒素 - 该化学物质在工作环境中可能对肾脏有毒。 催泪剂（催泪瓦斯）- 刺激眼睛并引起流泪的物质。

Neurotoxin - Other CNS neurotoxin Nephrotoxin - The chemical is potentially toxic to the kidneys in the occupational setting. Lacrimator (Lachrymator) - A substance that irritates the eyes and induces the flow of tears.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 毒性数据

LC50（小鼠）= 200毫克/立方米/2小时

LC50 (mice) = 200 mg/m3/2h

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

毒理性

• 非人类毒性摘录

一系列含有碘甲基、烷氧甲基和烷基氨基甲基基团的环氧烷被合成。这些化合物在小鼠和猫中的毒性和支气管扩张活性被确定。含碘和烷氧基的环氧烷毒性较低，而含氮的环氧烷比合成初期产物3,3-双(氯甲基)环氧烷毒性更高。所有含有环氧烷环的化合物都表现出显著的支气管扩张效果。3-(氯甲基)-3-(丁氧甲基)环氧烷、3,3-双(丙氧甲基)环氧烷和3-(氯甲基)-3-(碘甲基)环氧烷具有与乙基吗啡相同的支气管扩张效果。

A series of oxetanes containing iodomethyl, alkoxymethyl, and alkylaminomethyl groups were synthesized. The toxicity and broncholytic activity of these compounds were determined in mice and cats. Iodo- and alkyloxy-containing oxetanes possessed lower toxicity, and N-containing oxetanes had higher toxicity than 3,3-bis(chloromethyl)oxetane, the initial product of the synthesis. All compounds containing oxetane ring manifested a pronounced broncholytic effect. 3-(Chloromethyl)-3-(butoxymethyl)oxetane, 3,3-bis(propoxymethyl)oxetane, and 3-(chloromethyl)-3-(iodomethyl)oxetane possessed the same broncholytic effect, as that of euphyllin.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险等级：
  6.1(b)
• 危险品标志：
  T+
• 安全说明：
  S23,S26,S36/37/39,S45
• 危险类别码：
  R22
• RTECS号：
  RQ6826000
• 海关编码：
  2932999099
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 危险品运输编号：
  2810
• 储存条件：
  库房应保持通风、低温和干燥，并将储存物品与食品原料分开存放。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3,3-Bis(chloromethyl)oxetane
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 78-71-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C5H8Cl2O
Molecular Weight : 155,02 g/mol
CAS-No. : 78-71-7
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3,3-Bis(chloromethyl)oxetane
CAS-No. 78-71-7 Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3,3-Bis(chloromethyl)oxetane
CAS-No. 78-71-7 Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

类别：有毒物品

毒性分级：高毒

急性毒性：

• 口服 - 大鼠 LD50: 600 毫克/公斤
• 口服 - 小鼠 LD50: 420 毫克/公斤

可燃性危险特性：

• 可燃；燃烧时产生有毒氯化物烟雾

储运特性：

• 库房需通风、低温干燥
• 与食品原料分开存放

灭火剂：

• 干粉
• 泡沫
• 沙土
• 二氧化碳
• 雾状水

反应信息

• 作为反应物：
  描述：

  3,3-双(氯甲基)氧杂环丁烷 在 氯化二乙基铝 作用下， 生成 3-氯-2,2-二(氯甲基)丙-1-醇
  参考文献：
  名称：

  烷基铝化合物与环醚的反应

  摘要：

  氧杂环丁烷及其3,3-二甲基和3,3-双（氯甲基）衍生物与Et 2 AIX进行开环反应。当X ＝ H或Cl时，随后水解得到相应的丙醇或3-氯丙醇，但是当X ＝ CN时，分离出的产物是丁内酯。在升高的温度下，氧杂环丁烷与三乙基铝反应生成1-丙醇和1-戊醇，但3,3-二取代的氧杂环丁烷仅生成丙醇。Friedel-Crafts烷基化与氧杂环丁烷在异丙苯中与三乙基铝反应时伴随烷基化和还原。在升高的温度下，四氢呋喃和四氢吡喃与氢化二乙基铝反应，分别得到1-丁醇和1-戊醇。

  DOI：

  10.1016/s0022-328x(00)87664-0
• 作为产物：
  描述：

  3-氯-2,2-二(氯甲基)丙-1-醇 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 3,3-双(氯甲基)氧杂环丁烷
  参考文献：
  名称：

  聚[3-氯甲基-3-（1,1,2,2-四氢-全氟-辛基-氧基）甲基氧杂环丁烷]的合成及性能

  摘要：

  聚[3-氯甲基-3-（1,1,2,2-四氢-全氟-辛基-氧基）甲基氧杂环丁烷]的合成已分四个步骤进行。季戊四醇的氯化产生卤化醇的混合物，其在碱性介质中产生羟基化和氯化的氧杂环丁烷的混合物。其中，将双（3-氯甲基）氧杂环丁烷（BCMO）通过相转移催化与C 6 F 13 C 2 H 4 OH醚化，得到单取代和二取代的氟化氧杂环丁烷。在最后一步中，使用BF 3 ·OEt 2作为催化剂对单取代的氧杂环丁烷进行阳离子聚合，其特征在于1 H和1313 C NMR光谱。最后，已经确定了几种物理性质，例如粘度，玻璃化转变和分解温度以及表面性质。

  DOI：

  10.1016/s0022-1139(00)80471-6
• 作为试剂：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 3,3-双(氯甲基)氧杂环丁烷 、 丙酮 作用下， 生成 3-chloromethyl-3-thiocyanatomethyl-oxetane 、 3,3-bis(thiocyanatomethyl)oxetane
  参考文献：
  名称：

  Some Reactions of 3,3-Bis(chloromethyl)oxetane

  摘要：

  DOI：

  10.1021/jo01360a008

文献信息

• [EN] NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS NMDA ET UTILISATIONS DE CEUX-CI
  申请人：CADENT THERAPEUTICS

  公开号：WO2018119374A1

  公开（公告）日：2018-06-28

  Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

  本文披露了部分杂芳化合物及其在治疗神经精神障碍，例如精神分裂症和重度抑郁症中的用途方法。提供了药物组合物和制备杂芳化合物的方法。这些化合物被认为可以调节NMDA受体。
• Synthesis and Properties of 2-Oxa-6-azaspiro[3.3]heptane Sulfonate Salts
  作者：Richard van der Haas、Jeroen Dekker、Jorma Hassfeld、Anastasia Hager、Peter Fey、Philipp Rubenbauer、Eric Damen

  DOI：10.1055/s-0036-1588733

  日期：2017.6

  2-oxa-6-azaspiro[3.3]heptane is presented. While this compound is often isolated as an oxalate salt, its isolation as a sulfonic acid salt yields a more stable and more soluble product. With these improved properties access to a wider range of reaction conditions with the spirobicyclic 2-oxa-6-azaspiro[3.3]heptane has been enabled. An improved synthesis of the bicyclic spiro compound 2-oxa-6-azaspiro[3.3]heptane is

  摘要 提出了一种改进的双环螺化合物2-oxa-6-azaspiro [3.3]庚烷的合成。尽管该化合物通常以草酸盐的形式分离，但以磺酸盐的形式分离会产生更稳定和更易溶的产物。通过这些改进的性质，已经能够与螺双环2-氧杂-6-氮杂螺并[3.3]庚烷接触更广泛的反应条件。 提出了一种改进的双环螺化合物2-oxa-6-azaspiro [3.3]庚烷的合成。尽管该化合物通常以草酸盐的形式分离，但以磺酸盐的形式分离会产生更稳定和更易溶的产物。通过这些改进的性质，已经能够与螺双环2-氧杂-6-氮杂螺并[3.3]庚烷接触更广泛的反应条件。
• [EN] POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT<br/>[FR] COMPOSITION POLYMÉRISABLE COMPRENANT UN SULFONATE D'OXIME EN TANT QU'AGENT DE DURCISSEMENT THERMIQUE
  申请人：BASF SE

  公开号：WO2012101245A1

  公开（公告）日：2012-08-02

  The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula (I) QAaBbCc where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a + b + c is 1, 2, 3, 4 or 6 where (A) is a group (B) is a group (C) is a group where # denotes the point of attachment to Q; X is S or NR14 and Q, R1, R2, R3 and R14 are as defined in claim 1 and in the description. The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

  本发明涉及一种可聚合的组成，包括至少一种乙炔基不饱和的可聚合化合物和至少一种具有公式（I）QAaBbCc的亚硝基亚磺酸酯化合物，其中a为0、1、2、3、4或6，b为0、1、2、3、4或6，c为0、1、2、3、4或6，其中a+b+c的总和为1、2、3、4或6，其中（A）是一个基团，（B）是一个基团，（C）是一个基团，其中#表示与Q连接的点；X是S或NR14，Q、R1、R2、R3和R14如权利要求1和说明书中所定义。本发明还涉及使用这种组成物，新型亚硝基亚磺酸酯及其作为热固化促进剂的应用。
• [EN] SULFONIUM SULFATES, THEIR PREPARATION AND USE<br/>[FR] SULFATES DE SULFONIUM, LEUR PRÉPARATION ET UTILISATION
  申请人：BASF SE

  公开号：WO2012113829A1

  公开（公告）日：2012-08-30

  The present invention relates to a heat-curable composition comprising (a) at least one compound which is capable of undergoing cationic polymerization; and (b) at least one sulfonium sulfate selected from compounds of the formulae Ia and Ib where Yn- is a monovalent or divalent anion selected from (1) where n, M, R1 to R10 are as defined in claim 1 and in the description. The present invention also relates to novel sulfonium sulfates of the formulae Ia and Ib, to a process for curing cationically polymerizable material and to the cured material obtained by said process.

  本发明涉及一种热固化组合物，包括（a）至少一种能够进行阳离子聚合的化合物；和（b）选择自式Ia和Ib的至少一种砜酸盐，其中Yn-是从（1）中选择的一价或二价阴离子，其中n、M、R1至R10如权利要求1和描述中所定义。本发明还涉及式Ia和Ib的新型砜酸盐，以及用于固化阳离子聚合材料的工艺和通过该工艺获得的固化材料。
• [EN] 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES<br/>[FR] [1,2-C]PYRIMIDINES 5,7-IMIDAZO-SUBSTITUÉES COMME INHIBITEURS DE JAK KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011130146A1

  公开（公告）日：2011-10-20

  Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

  化合物的化学式I：（应在此处插入化学式），以及其立体异构体和药学上可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R5、R6、R7、X1和X2的含义如规范中所述，是一种或多种JAK激酶的抑制剂，并且在治疗自身免疫疾病、炎症性疾病、移植器官、组织和细胞的排斥反应、以及血液学紊乱和恶性肿瘤及其共病症方面具有用处。

表征谱图